FCA BEC - Bionomics Financial Controller
| BNOX Stock | USD 0.30 0.02 7.14% |
Executive
FCA BEC is Financial Controller of Bionomics Ltd ADR
| Age | 72 |
| Address | 200 Greenhill Road, Eastwood, SA, Australia, 5063 |
| Phone | 61 8 8150 7400 |
| Web | https://www.bionomics.com.au |
Bionomics Management Efficiency
The company has return on total asset (ROA) of (0.3958) % which means that it has lost $0.3958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7844) %, meaning that it created substantial loss on money invested by shareholders. Bionomics' management efficiency ratios could be used to measure how well Bionomics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -1,549 in 2024. Return On Capital Employed is likely to rise to -1,036 in 2024. At this time, Bionomics' Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 19.7 M in 2024, whereas Other Current Assets are likely to drop slightly above 291.1 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Michael Deperro | Rezolute | N/A | |
| Michael Carulli | Pmv Pharmaceuticals | 50 | |
| Daron Evans | Rezolute | 50 | |
| Susan Fischer | Aerovate Therapeutics | N/A | |
| Marinus Verwijs | Aerovate Therapeutics | 48 | |
| Gopal MBBS | Rezolute | N/A | |
| Dr MBA | Acrivon Therapeutics, Common | N/A | |
| Robert JD | Pmv Pharmaceuticals | 62 | |
| Stephen Yu | Aerovate Therapeutics | N/A | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Erin OBoyle | Rezolute | N/A | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Xiaohong She | Adagene | 57 | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Katharine CPA | Acrivon Therapeutics, Common | N/A | |
| MaryAlice JD | Acrivon Therapeutics, Common | 50 | |
| Yan MBA | Adagene | 49 | |
| Michael Covarrubias | Rezolute | N/A | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Binh Vu | Pmv Pharmaceuticals | N/A | |
| MS MBA | Rezolute | 50 | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 |
Bionomics ADR Leadership Team
Elected by the shareholders, the Bionomics' board of directors comprises two types of representatives: Bionomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bionomics. The board's role is to monitor Bionomics' management team and ensure that shareholders' interests are well served. Bionomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bionomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Spyridon MD, President CEO | ||
| Elizabeth Doolin, Senior Development | ||
| DCPSA FFPM, Consultant Neuroscience | ||
| Errol Souza, Ex Chairman | ||
| FCA BEC, Financial Controller | ||
| FCIS BCom, Company Secretary | ||
| MD DFAPA, Acting Officer | ||
| Julie Kerner, Senior Operations | ||
| Connor MSc, VP Devel |
Bionomics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bionomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | 89.10 % | ||||
| Current Valuation | (1.97 M) | ||||
| Shares Outstanding | 19.53 M | ||||
| Shares Owned By Insiders | 33.91 % | ||||
| Shares Owned By Institutions | 16.22 % | ||||
| Number Of Shares Shorted | 384.28 K | ||||
| Price To Book | 0.34 X | ||||
| Price To Sales | 386.72 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bionomics Stock Analysis
When running Bionomics' price analysis, check to measure Bionomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bionomics is operating at the current time. Most of Bionomics' value examination focuses on studying past and present price action to predict the probability of Bionomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bionomics' price. Additionally, you may evaluate how the addition of Bionomics to your portfolios can decrease your overall portfolio volatility.